Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    Clinical Characteristics and outcomes in HBV carriers TRANS with COVID-19 in WuHan, China: a retrospective cohort study

    Authors: Jingjing Lu; Mu Hu; Xia Zhou; Hui Zhu; Feilong Wang; Jianhao Huang; Zhongliang Guo; Qiang Li; Qi Yin; Zhifeng Yang

    doi:10.21203/rs.3.rs-42476/v1 Date: 2020-07-13 Source: ResearchSquare

    Background: Coronavirus 2019 (COVID-19) is a novel infectious disease MESHD that was first reported in Wuhan, China, but has spread to all parts of the world. At the same time, because China has millions of HBV carriers TRANS, HBV infection MESHD has become a major public health problem in China. In this study, we aim to describe the clinical features of HBV carriers TRANS (AsC) infected with COVID-19 and to assess the factors that may affect the outcome during disease progression.Methods: This retrospective cohort study included 72 patients diagnosed with COVID-19 in Wuhan Jinyintan Hospital. These patients were also diagnosed as HBV carriers TRANS. The epidemiological characteristics, demographic features, clinical manifestations, laboratory test, treatment, management and final outcome were collected and analyzed.Results: The median age TRANS of 72 patients is 58.5 years old, of which 55.56% (n=40) are male TRANS. 20 (30.56%) patients were severe cases and 50 (69.44%) were non-severe cases. Fever HP Fever MESHD is the most common symptom, followed by cough HP, chest tightness HP chest tightness MESHD and sputum. Laboratory test results including hematologic, biochemical, infection MESHD and coagulation parameters and several indicators, such as Aspartate Aminotransferase (AST), Total Bilirubin (TBil), Direct Bilirubin (DBil), Indirect Bilirubin (IBil), γ-glutamyl Transferase (GGT) showed difference between their admission and discharge. The level of Prealbumin (PA) and Serum SERO Amyloid A (SAA) in the study showed a significant trend from high to low, which has statistical significance.Conclusions: The clinical features of HBV carriers TRANS with COVID-19 have obvious systemic symptoms, such as fever HP fever MESHD, cough HP cough MESHD, and chest tightness HP chest tightness MESHD. Compared with liver function data on admission and discharge, SARS-CoV-2 does not directly activate the Hepatitis HP Hepatitis MESHD B virus, and the risk of liver cell damage of HBV carriers TRANS with COVID-19 does not increase. Both PA and SAA are sensitive indicators and can be used to evaluate the prognosis and outcome of these patients.

    COVID-19 transmission risk TRANS factors

    Authors: Alessio Notari; Giorgio Torrieri

    doi:10.1101/2020.05.08.20095083 Date: 2020-05-12 Source: medRxiv

    We analyze risk factors correlated with the initial transmission TRANS growth rate of the recent COVID-19 pandemic in different countries. The number of cases follows in its early stages an almost exponential expansion; we chose as a starting point in each country the first day with 30 cases and we used 12 days, capturing thus the early exponential growth. We looked then for linear correlations of the exponents with other variables, for a sample of 126 countries. We find a positive correlation, faster spread of COVID-19 , with high confidence level with the following variables, with respective p-value: low Temperature (4x10 -7), high ratio of old vs. working- age TRANS people (3x10 -6), life expectancy (8x10 -6), number of international tourists (1x10 -5), earlier epidemic starting date (2x10 -5), high level of physical contact in greeting habits (6x10 -5), lung cancer MESHD prevalence SERO (6x10 -5), obesity HP obesity MESHD in males TRANS (1x10 -4), share of population in urban areas (2x10 -4), cancer MESHD prevalence SERO (3x10 -4), alcohol consumption (0.0019), daily smoking prevalence SERO (0.0036), UV index (0.004, smaller sample, 73 countries), low Vitamin D serum SERO levels (0.002-0.006, smaller sample, 50 countries). There is highly significant correlation also with blood SERO type: positive correlation with types RH- (2x10 -5) and A+ (2x10 -3), negative correlation with B+ (2x10 -4). We also find positive correlation with moderate confidence level (p-value of 0.02-0.03) with: CO2/SO emissions, type-1 diabetes MESHD in children TRANS, low vaccination coverage for Tuberculosis MESHD (BCG). Several of the above variables are correlated with each other and so they are likely to have common interpretations. Other variables are found to have a counterintuitive negative correlation, which may be explained due their strong negative correlation with life expectancy: slower spread of COVID-19 is correlated with high death-rate due to pollution, prevalence SERO of anemia HP anemia MESHD and hepatitis HP hepatitis MESHD B, high blood SERO pressure in females TRANS. We also analyzed the possible existence of a bias: countries with low GDP-per capita, typically located in warm regions, might have less intense testing and we discuss correlation with the above variables.

    Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis

    Authors: Wei-jie Guan; Wen-hua Liang; Yi Zhao; Heng-rui Liang; Zi-sheng Chen; Yi-min Li; Xiao-qing Liu; Ru-chong Chen; Chun-li Tang; Tao Wang; Chun-quan Ou; Li Li; Ping-yan Chen; Ling Sang; Wei Wang; Jian-fu Li; Cai-chen Li; Li-min Ou; Bo Cheng; Shan Xiong; Zheng-yi Ni; Yu Hu; Jie Xiang; Lei Liu; Hong Shan; Chun-liang Lei; Yi-xiang Peng; Li Wei; Yong Liu; Ya-hua Hu; Peng Peng; Jian-ming Wang; Ji-yang Liu; Zhong Chen; Gang Li; Zhi-jian Zheng; Shao-qin Qiu; Jie Luo; Chang-jiang Ye; Shao-yong Zhu; Lin-ling Cheng; Feng Ye; Shi-yue Li; Jin-ping Zheng; Nuo-fu Zhang; Nan-shan Zhong; Jian-xing He

    doi:10.1101/2020.02.25.20027664 Date: 2020-02-27 Source: medRxiv

    Objective: To evaluate the spectrum of comorbidities and its impact on the clinical outcome in patients with coronavirus disease MESHD 2019 (COVID-19). Design: Retrospective case studies Setting: 575 hospitals in 31 province/autonomous regions/provincial municipalities across China Participants: 1,590 laboratory-confirmed hospitalized patients. Data were collected from November 21st, 2019 to January 31st, 2020. Main outcomes and measures: Epidemiological and clinical variables (in particular, comorbidities) were extracted from medical charts. The disease severity was categorized based on the American Thoracic Society guidelines for community-acquired pneumonia HP pneumonia MESHD. The primary endpoint was the composite endpoints, which consisted of the admission to intensive care unit (ICU), or invasive ventilation, or death MESHD. The risk of reaching to the composite endpoints was compared among patients with COVID-19 according to the presence and number of comorbidities. Results: Of the 1,590 cases, the mean age TRANS was 48.9 years. 686 patients (42.7%) were females TRANS. 647 (40.7%) patients were managed inside Hubei province, and 1,334 (83.9%) patients had a contact history of Wuhan city. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached to the composite endpoints. 399 (25.1%) reported having at least one comorbidity. 269 (16.9%), 59 (3.7%), 30 (1.9%), 130 (8.2%), 28 (1.8%), 24 (1.5%), 21 (1.3%), 18 (1.1%) and 3 (0.2%) patients reported having hypertension HP hypertension MESHD, cardiovascular diseases MESHD, cerebrovascular diseases MESHD, diabetes MESHD, hepatitis HP hepatitis MESHD B infections, chronic HP chronic obstructive pulmonary disease MESHD obstructive pulmonary disease, chronic HP chronic kidney diseases MESHD, malignancy and immunodeficiency MESHD immunodeficiency HP, respectively. 130 (8.2%) patients reported having two or more comorbidities. Patients with two or more comorbidities had significantly escalated risks of reaching to the composite endpoint compared with those who had a single comorbidity, and even more so as compared with those without (all P<0.05). After adjusting for age TRANS and smoking status, patients with COPD MESHD (HR 2.681, 95%CI 1.424-5.048), diabetes MESHD (HR 1.59, 95%CI 1.03-2.45), hypertension HP hypertension MESHD (HR 1.58, 95%CI 1.07-2.32) and malignancy MESHD (HR 3.50, 95%CI 1.60-7.64) were more likely to reach to the composite endpoints than those without. As compared with patients without comorbidity, the HR (95%CI) was 1.79 (95%CI 1.16-2.77) among patients with at least one comorbidity and 2.59 (95%CI 1.61-4.17) among patients with two or more comorbidities. Conclusion: Comorbidities are present in around one fourth of patients with COVID-19 in China, and predispose to poorer clinical outcomes.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.